BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 8005645)

  • 1. Some behavioural effects of chloroquine in rats suggesting dopaminergic activation.
    Amabeoku GJ
    Indian J Med Res; 1994 Feb; 99():87-94. PubMed ID: 8005645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of buspirone on dopamine dependent behaviours in rats.
    Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
    Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dextromethorphan on dopamine dependent behaviours in rats.
    Gaikwad RV; Gaonkar RK; Jadhav SA; Thorat VM; Jadhav JH; Balsara JJ
    Indian J Exp Biol; 2007 Aug; 45(8):712-9. PubMed ID: 17877148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats].
    Minematsu N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Jun; 15(3):247-52. PubMed ID: 7584718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic nicotine treatment potentiates behavioral responses to dopaminergic drugs in rats.
    Suemaru K; Gomita Y; Furuno K; Araki Y
    Pharmacol Biochem Behav; 1993 Sep; 46(1):135-9. PubMed ID: 7902980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of yohimbine on dopamine dependent behaviours in rats and mice.
    Bende MM; Bapat TR; Balsara JJ; Chandorkar AG
    Indian J Physiol Pharmacol; 1990 Jul; 34(3):195-200. PubMed ID: 2286423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dexfenfluramine on dopamine dependent behaviours in rats.
    Thorat VM; Gaonkar RK; Bhosale KB; Balsara JJ
    Indian J Physiol Pharmacol; 2005 Jan; 49(1):39-48. PubMed ID: 15881857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some central effects of angiotensin II. Interactions with dopaminergic transmission.
    Georgiev V; György L; Getova D; Markovska V
    Acta Physiol Pharmacol Bulg; 1985; 11(4):19-26. PubMed ID: 3012944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the participation of the dopaminergic system in the central effects of chelidonine.
    Kleinrok Z; Szponar J; Matuszek B; Jagiełło-Wójtowicz E
    Pol J Pharmacol Pharm; 1990; 42(5):417-24. PubMed ID: 2098751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats.
    Perry JC; Vital MA; Frussa-Filho R; Tufik S; Palermo-Neto J
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):127-33. PubMed ID: 15013028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solcoseryl stimulates behavioural activity of rats.
    Braszko JJ; Winnicka MM; Wiśniewski K
    Acta Physiol Hung; 1996; 84(1):63-72. PubMed ID: 8993676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
    Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
    Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic influence on the effects of angiotensin II in behavioural reactions.
    Georgiev V; György L; Yonkov D; Getova D; Markovska V; Petkova B
    Physiol Bohemoslov; 1985; 34 Suppl():45-8. PubMed ID: 3014581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat.
    Lipska BK; Jaskiw GE; Braun AR; Weinberger DR
    Biol Psychiatry; 1995 Aug; 38(4):255-62. PubMed ID: 8547448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injection of apomorphine--a test to predict individual different dopaminergic sensitivity?
    Surmann A; Havemann-Reinecke U
    J Neural Transm Suppl; 1995; 45():143-55. PubMed ID: 8748620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of fibrinopeptides A and B with dopaminergic receptors in central nervous system.
    Wawrzyniuk I; Buczko W; Wiśniewski K
    Pol J Pharmacol Pharm; 1979; 31(4):365-72. PubMed ID: 574959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioural effects of drugs acting on the central dopaminergic neurons.
    Georgiev V; Markovska V
    Act Nerv Super (Praha); 1977 Jul; 19 Suppl 2():335-6. PubMed ID: 575925
    [No Abstract]   [Full Text] [Related]  

  • 19. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
    Christensen AV; Arnt J; Hyttel J; Svendsen O
    Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the participation of the dopaminergic transmission system in the effects of two newly synthesized barbiturates.
    Getova D; Markovska V
    Acta Physiol Pharmacol Bulg; 1988; 14(2):56-62. PubMed ID: 2851915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.